Yunpeng Yang

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Li Zhang, Yan Huang, Shaodong Hong et al. · The Lancet · 2016 · 515 citations

Cisplatin Versus Fluorouracil, Medicine, Metronomic Therapy +6

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

Wenfeng Fang, Yunpeng Yang, Yuxiang Ma et al. · The Lancet Oncology · 2018 · 495 citations

Medicine, Immunology, Pathology +8

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Yunpeng Yang, Song Qu, Jingao Li et al. · The Lancet Oncology · 2021 · 429 citations

Medicine, Clinical Trials, Immune Checkpoint Inhibitor +8

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

Wenfeng Fang, Jianwei Zhang, Shaodong Hong et al. · Oncotarget · 2014 · 382 citations · Full text

Immunology, Immune Regulation, Cell Death +22

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yunpeng Yang, Zhehai Wang, Jian Fang et al. · Journal of Thoracic Oncology · 2020 · 376 citations · Full text